Due to past success in testing and gaining regulatory approval for a variety of therapies in multiple sclerosis (MS), the conduct of future clinical trials has become increasingly problematic. An international workshop has met to discuss the issues facing the MS clinical trial community and to examine possible new strategies for the design of trials. Particular focus has been placed on trials that either avoid the use of a placebo because of ethical considerations or on designs that allow new therapies to be studied more rapidly or with fewer patients than needed in a conventional placebo-controlled trial. The discussions resulting from the workshop should provide a basis for the examination and implementation of innovative clinical trial designs in MS.
Goodin DS , Frohman EM , Garmany GP Jr , Halper J , Likosky WH , Lublin FDet al.Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines . Neurology2002; 58: 169-178 .
2.
Herndon R.Multiple sclerosis. Proceedings of the International Conference on Therapeutic Trials in Multiple Sclerosis, Grand Island, NY, April, 23-24, 1982 . Arch Neurol1983; 40: 663-710 .
Bland JM , Kerr D.Fifth revision of Declaration of Helsinki. Clause 29 forbids trials from using placebos when effective treatment exists . BMJ2002; 324: 975-975 .
5.
Lublin FD , Reingold SC.Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS . Ann Neurol2001; 49: 677-681 .
6.
Coste J , Fermanian J , Venot A.Methodological and statistical problems in the construction of composite measurement scales: a survey of six medical and epidemiological journals . Stat Med1995; 14: 331-345 .
7.
Petkau AJ.Statistical and design considerations for multiple sclerosis clinical trials. In Goodkin DE , Rudick RA eds. Multiple sclerosis: advances in clinical trials. London: Springer-Verlag , 1996: 63-103.
8.
Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology1983; 33: 1444-1452 .
9.
Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer Jet al.Clinical outcomes assessment in multiple sclerosis . Ann Neurol1996; 40: 469-479 .
10.
Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer Jet al.Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol1997; 42: 379-382 .
11.
Wolinsky JS , Narayana PA , Noseworthy JH , Lublin FD , Whitaker JN , Linde Aet al.Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators . Neurology2000; 54: 1734-1741 .
12.
Pocock SJ , Geller NL , Tsiatis AA.The analysis of multiple endpoints in clinical trials . Biometrics1987; 43: 487-498 .
13.
O’Brien PC.Procedures for comparing samples with multiple endpoints . Biometrics1984; 40: 1079-1087 .
14.
Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrissey SPet al.Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial . Lancet2002; 360: 2018-2025 .
15.
Follmann D , Wittes J , Cutler JA.The use of subjective rankings in clinical trials with an application to cardiovascular disease . Stat Med1992; 11: 427-437 ; discussion 439-54.
16.
Thall PF , Russell KE.A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I-II clinical trials . Biometrics1998; 54: 251-264 .
17.
Krams M , Lees KR , Hacke W , Grieve AP , Orgogozo JM , Ford GA.Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke . Stroke2003; 34: 2543-2548 .
18.
Rosenberger WF , Lachin JM.Randomization in clinical trials: theory and practice. New York: Wiley , 2002.
19.
Follmann DA , Proschan MA , Geller NL.Monitoring pairwise comparisons in multi-armed clinical trials . Biometrics1994; 50: 325-336 .
20.
Noseworthy J , Kappos L , Daumer M.Competing interests in multiple sclerosis research . Lancet2003; 361: 350-351 .
21.
Prentice RL.Surrogate endpoints in clinical trials: definition and operational criteria . Stat Med1989; 8: 431-440 .
22.
Fleming TR , DeMets DL.Surrogate end points in clinical trials: are we being misled ? Ann Intern Med1996; 125: 605-613 .
23.
Daniels MJ , Hughes MD.Meta-analysis for the evaluation of potential surrogate markers . Stat Med1997; 16: 1965-1982 .
24.
Spiegelhalter DJ , Freedman LS , Parmar MK.Bayesian approaches to clinical trials and health care evaluation. New York: Wiley , 2004.
25.
Berry D , Stangl D.Bayesian statistics. New York: Marcel Dekker , 1996.
26.
Thall PF , Wathen JK , Bekele BN , Champlin RE , Baker LH , Benjamin RS.Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes . Stat Med2003; 22: 763-780 .
27.
Kappos L , Weinshenker B , Pozzilli C , Thompson AJ , Dahlke F , Beckmann Ket al.Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials . Neurology2004; 63: 1779-1787 .
28.
Prineas JW , Barnard RO , Kwon EE , Sharer LR , Cho ES.Multiple sclerosis: remyelination of nascent lesions . Ann Neurol1993; 33: 137-151 .
29.
Weinshenker BG , O’Brien PC , Petterson TM , Noseworthy JH , Lucchinetti CF , Dodick DWet al.A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease . Ann Neurol1999; 46: 878-886 .
